N°64 - Marché /Nutrition clinique Finally, Nestlé acquired Atrium Innovations lable in 35 references (soups, drinks, creams, (Canada), whose “portfolio will extend our jellied waters). product range with value-added solutions such as probiotics, plant-based protein Oral nutrition products nutrition, meal replacements and an exten- get specialized sive multivitamin line,” Greg Behar said. This acquisition strategy, which balances Nestlé’s • Paediatric solutions for allergies portfolio between consumer care (prevention) Cow’s-milk protein allergy continues to inspire and medical nutrition (therapy) has a major the industry. Nutricia Advanced Medical advantage, according to Greg Behar, former Nutrition expands its Neocate range with® player in the pharma sector: “Novel thera- two innovations: Neocate Spoon, a cream® peutic nutrition have a risk pro le much lower product to reconstitute and Neocate Splash,® than in pharma and a much faster develop- a ready-to-feed milk for allergic infants and ment.” children. Nestlé has developed a range of The third player, Mead Johnson, had a tur- infant formulas - Alfamino, Althéra and Alfaré- nover of $3,85 billion in 2017, mostly gene- that the group supplements by developing an rated by Enfsa range sales on the Asian market awareness tool to help physicians detect aller- (49% as compared to 32% in Europe, North gies at an earlier stage thanks to a skin test America and 17% in Latin America). Two inno- for the diagnosis of cow’s milk protein allergy. vations, Enfamil Neuro Pro (enriched with® DHA) and Enfamil MFGM (milk fat globule® • Non-alcoholic steatohepatitis membranes) have boosted sales recently. The In 2017, Nestlé jointly developed with Pro- American brand has recently been acquired meteus Lab diagnostic a new, non-invasive by Reckitt Benckiser Group Pic, global leader tool, the Fibrospect NASH test to help® in the sectors of health, hygiene and home healthcare professionals determine the 014 products (June 2017). With this purchase, the severity of nonalcoholic fatty liver disease British group aims to recentre its activity on (NAFLD - excessive fat accumulation in the consumer healthcare, a fi eld that currently liver). Its prevalence has doubled over the generates 80% of its revenues (2017 Annual past 20 years (it concerns 25% of the Ame- Report). rican population) and currently represents Nutricia Advanced Medical Nutrition the fi rst cause of liver diseases in Western (Danone) is ranked as the fourth global leader countries. This new tool could replace liver and as a leading player in Europe (2017 Annual biopsy, an invasive procedure currently Report). In 2017, the Advanced Medical Nutri- used to determine the stage of the disease. tion business saw its sales (€1.68 million During the same year, BASF identifi ed bio- except for classic infant nutrition products) logical markers (metabolomic signature) rise by over +5% and registered a turnover allowing for the assessment of the stage of increase of 0-5% in all regions, especially in development of nonalcoholic steatohepatitis China, Turkey and Latin America. All product and then it partnered up with DIEM Labs to segments (adult and paediatric care) are launch in early 2018 Hepaxa, a concentrate concerned. But the profi ts are even more (90%) ofEPA and DHA long-chainomega-3 visible with leading brands such as Neocate, fattyacids, the fi rst medical food for sub- Nutrison and Nutrini. Hypoallergenic formu- jects with an early stage of development of lations such as Neocate Splash and Neocate thedisease (before fi brosis an cirrhosis) Ad . Syneo have also boosted the market. clinical trial conducted in170 subects withj As for the discreet Fresenius Kabi, it has NAFLD proved its effectiveness. - for a large part of its portfolio - products Asfor the French compan Viyalbotis, it is cur- with leading positioning on the European rently developing VAL-63 NAFLD, a health market and signifi cant market shares on the supplement for patientswithNFL as elADwl fast-growing markets of Asia-Pacifi c and Latin as amedical nutrition product, VAL-30 fo6 r America. Clinical nutrition (enteral, parenteral, thepeople diagnosed with NSH(steaoe-A th oral) generated $1.7 billion in 2017. It is a patitis worsened by inflammatioann dliver global leader in the sector of parenteral nutri- cell injuries), which is tobe lauchedonhn te tion. Its oral nutrition range, Fresubin, is avai-® market in 2021. ■ / Juillet - Août - Septembre 2018 / N°64 / L’Actualité des Ingrédients Fonctionnels & Santé